文献速递MDS 与骨髓增殖性肿瘤

干扰素α治疗真性红细胞增多症改善无骨髓纤维化生存和总生存

Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival.
PubMed 文献 · Leukemia · 2021-03-02

这项单中心回顾性研究纳入470例真性红细胞增多症患者,比较干扰素α与羟基脲、单纯放血治疗。干扰素α组20年无骨髓纤维化生存更低危患者中更高,高危患者总生存更优,多因素分析显示干扰素α使用时间越长,骨髓纤维化风险和死亡风险越低。

要点

  • 低危患者20年无骨髓纤维化生存:干扰素α 84% vs 羟基脲 65% vs 单纯放血 55%(p<0.001)。
  • 高危患者20年总生存:干扰素α 66% vs 羟基脲 40% vs 单纯放血 14%(p=0.016)。
  • 干扰素α使用时间越长,骨髓纤维化风险(HR 0.91)和死亡风险(HR 0.94)越低。

核心结论

  • 干扰素α治疗真性红细胞增多症可预防骨髓纤维化并可能延长生存。

研究设计与样本

  • 单中心回顾性研究,纳入470例真性红细胞增多症患者,中位年龄54岁,中位随访10年。

主要发现

  • 低危患者20年无骨髓纤维化生存:干扰素α 84%、羟基脲65%、单纯放血55%(p<0.001)。
  • 低危患者20年总生存:干扰素α 100%、羟基脲85%、单纯放血80%(p=0.44)。
  • 高危患者20年无骨髓纤维化生存:干扰素α 89%、羟基脲41%、单纯放血36%(p=0.19)。
  • 高危患者20年总生存:干扰素α 66%、羟基脲40%、单纯放血14%(p=0.016)。
  • 多因素分析:干扰素α使用时间越长,骨髓纤维化风险越低(HR 0.91,p<0.001),死亡风险越低(HR 0.94,p=0.012)。

临床怎么用

  • 对于真性红细胞增多症患者,可考虑使用干扰素α以降低骨髓纤维化风险并可能改善生存。

局限性

  • 回顾性单中心设计,治疗分组依据ELN风险评分存在差异(p<0.001),可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Interferon-alpha (rIFNα) is the only disease-modifying treatment for polycythemia vera (PV), but whether or not it prolongs survival is unknown. This large single center retrospective study of 470 PV patients compares the myelofibrosis-free survival (MFS) and overall survival (OS) with rIFNα to two other primary treatments, hydroxyurea (HU) and phlebotomy-only (PHL-O). The median age at diagnosis was 54 years (range 20-94) and the median follow-up was 10 years (range 0-45). Two hundred and twenty-nine patients were women (49%) and 208 were high-risk (44%). The primary treatment was rIFNα in 93 (20%), HU in 189 (40%), PHL-O in 133 (28%) and other cytoreductive drugs in 55 (12%). The treatment groups differed by ELN risk score (p < 0.001). In low-risk patients, 20-year MFS for rIFNα, HU, and PHL-O was 84%, 65% and 55% respectively (p < 0.001) and 20-year OS was 100%, 85% and 80% respectively (p = 0.44). In high-risk patients, 20-year MFS for rIFNα, HU, and PHL-O was 89%, 41% and 36% respectively (p = 0.19) and 20-year OS was 66%, 40%, 14% respectively (p = 0.016). In multivariable analysis, longer time on rIFNα was associated with a lower risk of myelofibrosis (HR: 0.91, p < 0.001) and lower mortality (HR: 0.94, p = 0.012). In conclusion, this study supports treatment of PV with rIFNα to prevent myelofibrosis and potentially prolong survival.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Abu-Zeinah G, Krichevsky S, Cruz T, et al. Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival. Leukemia. 2021. PMID: 33654206. doi:10.1038/s41375-021-01183-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。